Target Dose (Monotherapy/Combination): The common target dose used in major clinical trials is 2.4 mg per week
If symptoms become persistent or concerning, seeking professional advice can help identify the cause and ensure you receive appropriate support throughout your treatment journey
INGREDIENTS Glycerin (Coconut Derived), Medium Chain Triglycerides (Coconut Derived), Oleic Acid (From Olive Oil), Glutathione, Lactoferrin (Milk), Phosphatidylcholine, Natural Flavours (Orange Peel, Cinnamon Oil (bark), Clove Oil, Vanilla Extract), Vitamin E (as D Alpha Tocopherol), Stevia (Rebaudioside-A), Riboflavin and Meolybdenum
The American Gastroenterological Association's 2021 clinical practice update states that "any new-onset hematochezia or melena in a patient on a GLP-1 receptor agonist warrants the same urgent evaluation as in an untreated patient" [9]
4.3% with placebo), hypersensitivity, including severe reactions (3.2% vs